$INCY News

Saturday, Incyte's Phase 3 frontMIND Trial Of Tafasitamab (Monjuvi/Minjuvi) And Lenalidomide Added To R-CHOP Showed A 25% Reduction In Risk Of Disease Progression Or Death Versus R-CHOP For Previously Untreated Diffuse Large Or High-grade B-cell Lymphoma

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL

Why Is Incyte (INCY) Down 1.8% Since Last Earnings Report?

Incyte Sets Mid-Year Phase 3 Trial for CALR Antibody 989 as Pipeline Updates Roll Out

INCYTE CORP (NASDAQ:INCY) Shows Rare Alignment of High Growth Momentum and Technical Breakout Setup

Bernstein Initiates Coverage On Incyte with Market Perform Rating, Announces Price Target of $99

How Incyte’s AI-Powered R&D Partnerships At Incyte (INCY) Has Changed Its Investment Story

HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $135 Price Target

Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery

Incyte Corporation (INCY) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development

Incyte CEO Says Post-Jakafi Growth Path Is Clearer as Pipeline Catalysts Build

Incyte Corporation (INCY) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript

Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress

Incyte Corporation (INCY) Highlights Sustained Efficacy of Opzelura Through Week 24

Incyte's (NASDAQ:INCY) Promising Earnings May Rest On Soft Foundations

Does Jakafi XR Approval And Pipeline Progress Change The Bull Case For Incyte (INCY)?

Mirum's Q1 Earnings & Revenues Beat Estimates, 2026 View Raised

Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis

Incyte Reports Phase 3 TRuE-AD4 Week 24 Data Showing Opzelura Cream Maintained High Rates Of Disease Control And Symptom Relief In Adults With Moderate Atopic Dermatitis At EADV 2026